New Dividend: 20 cents quarterly (per share) Dividend Percent Increase: 5.3% Current Yield: 0.76% Medical device firm C.R. Bard ( BCR) is having a great year in 2012; shares of the $8.4 billion company have rallied more than 17% since the first trading day of January. Strictly speaking, Bard isn't a "dividend stock" it yields just 0.76%, putting it on the low end of the spectrum. But the sign management is sending by paying out more cash, coupled with awesome relative strength this year makes it worth taking a closer look at BCR nonetheless. >>3 Dividend Growth Stocks to Buy at Any Price Close to 90% of BCR's sales come from consumable products, a source of recurring highly sticky revenues that generally have higher margins since customer acquisition costs eventually approach nil over the long-term. With shares breaking out above the psychologically important $100 mark, BCR looks in good shape to continue to run. BCR was included in a list of the 10 Best Dividend Aristocrats for 2012.